Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth po ...

PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced the appointments of Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its Board of Directors. As part of their appointments, Dr. Lee will serve as a member of the Audit and the Compensation Committees and Dr. Murphy will serve as a member of the Compensation a ...

Summary of Century Therapeutics FY Conference Call Company Overview - **Company**: Century Therapeutics (NasdaqGS: IPSC) - **Focus**: Development of induced pluripotent stem cells (iPSCs) for CAR T cells and natural killer (NK) cells targeting autoimmune diseases and cancer [1][2] Key Developments - **CNTY813**: New program for iPSC-derived beta islet cells aimed at treating type 1 diabetes [1] - **CNTY308**: A CD19 CAR-iT cell therapy that is being developed for autoimmune diseases [1][19] Core Advantages of iPSC-Derived Therapies 1. **Engineerability**: Ability to harness synthetic biology for cell therapy [4] 2. **Characterization and Reproducibility**: High control over the differentiation process of iPSCs [4] 3. **Profitable Scalability**: Pathway to achieve antibody-like scale and cost efficiency [5] Alloevasion Technology - **Definition**: A set of genetic edits that allow iPSC-derived cells to coexist with the patient's immune system [6] - **Key Features**: - Removal of HLAs to prevent T cell engagement [7] - Introduction of a universal NK cell inhibitory ligand for protection against NK cells [8] - IgG degrading protease to mitigate antibody-mediated immunity [9][10] Clinical Development Plans - **CNTY813**: On track for IND-enabling stages by the end of 2025, with tumorigenicity studies underway [18] - **CNTY308**: Clinical trials planned to initiate next year, focusing primarily on autoimmune diseases [23][24] Market Opportunity - **Type 1 Diabetes**: Approximately 2 million patients in the U.S. and 9 million worldwide, presenting a significant unmet medical need [32] - **Autoimmune Diseases**: Over 50 million patients in the U.S., indicating a large potential market for CNTY308 [22] Partnerships and Future Plans - Continuous dialogue with pharmaceutical companies for potential partnerships, especially in Type 1 diabetes and autoimmune disease markets [31][32] - Exploration of regenerative medicine opportunities, including potential applications in Parkinson's disease and cardiac disease [36][38] Financial Position - **Cash Reserves**: Approximately $133 million, expected to fund operations into Q4 2027 [39] - **Upcoming Catalysts**: Clinical data generation for CNTY101 and CNTY308, and IND submission for type 1 diabetes expected in 2026 [39] Conclusion Century Therapeutics is positioned at the forefront of iPSC-derived cell therapies, with innovative approaches to address significant medical needs in autoimmune diseases and type 1 diabetes. The company's focus on Alloevasion technology and scalable manufacturing processes enhances its potential for success in the competitive biotech landscape.

Core Insights - Century Therapeutics is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies targeting autoimmune diseases and cancer [2] Company Participation - Century Therapeutics will participate in the Piper Sandler 37th Annual Healthcare Conference in New York, with a live webcast available on the company's Investors page [1] - An archived replay of the webcast will be accessible for at least 30 days following the event [1] Leadership Engagement - Chad Cowan, Ph.D., Chief Scientific Officer, will join the "State of the Art in Cell Therapy" panel discussion on December 2, 2025 [3] - Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Dr. Cowan will participate in a webcasted fireside chat on December 3, 2025 [3] Technology and Approach - The company utilizes its iPSC cell foundry and the Allo-Evasion™ technology to develop off-the-shelf cell therapies, aiming to enhance patient access and improve upon existing therapies [2]

Financial Performance - Century Therapeutics reported a net loss of $34.4 million for Q3 2025, compared to a net loss of $31.2 million in Q3 2024, reflecting a year-over-year increase in losses of approximately 7.3%[7] - Research and Development (R&D) expenses decreased to $22.5 million in Q3 2025 from $27.2 million in Q3 2024, a reduction of about 17.3%[6] - General and Administrative (G&A) expenses were $6.8 million for Q3 2025, down from $8.4 million in Q3 2024, representing a decrease of approximately 19%[6] - Total assets decreased to $244.7 million as of September 30, 2025, from $353.2 million as of December 31, 2024, a decline of approximately 30.7%[12] Cash Position - Cash, cash equivalents, and marketable securities totaled $132.7 million as of September 30, 2025, down from $220.1 million as of December 31, 2024, indicating a decrease of about 39.7%[6] - The company estimates its cash runway will support operations into the fourth quarter of 2027[4] Clinical Development - The company anticipates initiating IND-enabling studies for its lead beta islet program, CNTY-813, by the end of 2025, with an IND submission planned for as early as 2026[4] - CNTY-308 is progressing through IND-enabling studies, with clinical study initiation expected in 2026[4] - Century Therapeutics has generated compelling preclinical data for its iPSC-derived beta islet program, indicating potential for rapid and sustained glucose control without chronic immune suppression[3] - Initial clinical data from the CNTY-101 trial in CARAMEL is expected to be presented on December 5, 2025[6]

Development Programs - The company is developing CNTY-813 for Type 1 diabetes, with plans to move into IND-enabling studies by the end of 2025 and anticipate IND submission as early as 2026[140] - CNTY-308, a CD19-targeted CAR-iT cell therapy, is progressing towards clinical studies expected to start in 2026 following successful IND-enabling studies[141] Financial Performance - The company has not generated any revenue from product sales and does not expect to do so in the foreseeable future, relying on future collaborations for revenue[158] - Collaboration revenue for the nine months ended September 30, 2025, was $109.2 million, a significant increase from $2.4 million in 2024[176] - Total operating expenses for the three months ended September 30, 2025, were $36.1 million, slightly higher than $35.6 million in 2024[168] - Research and development expenses decreased to $22.5 million for the three months ended September 30, 2025, from $27.2 million in 2024, a reduction of $4.7 million[170] - General and administrative expenses were $6.8 million for the three months ended September 30, 2025, down from $8.4 million in 2024[171] - Interest income decreased to $1.6 million for the three months ended September 30, 2025, compared to $3.3 million in 2024[173] - The accumulated deficit as of September 30, 2025, was $772.7 million[183] Cash Flow and Financing - As of September 30, 2025, the company had cash and cash equivalents of $55.5 million and investments of $77.2 million[183] - The company anticipates needing to raise additional financing in the future to support ongoing operations and clinical trials[146] - Net cash used in operating activities was $87.8 million for the nine months ended September 30, 2025, compared to $85.9 million for the same period in 2024, reflecting a net income of $9.6 million and non-cash charges of $23.1 million[190] - Net cash provided by investing activities increased significantly to $85.1 million for the nine months ended September 30, 2025, from $16.9 million in the same period of 2024, primarily due to the sale of fixed maturity securities of $121.7 million[192] - Net cash provided by financing activities decreased to $0.1 million for the nine months ended September 30, 2025, down from $75.2 million in 2024, which included $17.8 million from an at-the-market capital raise and $56.6 million from PIPE financing[194] - The company reported a net decrease in cash, cash equivalents, and restricted cash of $2.5 million for the nine months ended September 30, 2025, compared to an increase of $6.1 million in 2024[189] - As of September 30, 2025, the company had cash, cash equivalents, and restricted cash totaling $58.7 million, along with investments of $77.2 million[206] Operational Changes - The company completed a workforce reduction of approximately 51% to focus on key clinical programs[143] - Bristol-Myers Squibb terminated its collaboration agreement effective March 12, 2025, which included a $100 million upfront payment and stock purchase[149] - The company is investing in manufacturing capabilities to improve efficiency and scalability of its iPSC cell therapy products[145] - Future capital requirements will depend on various factors, including the costs of clinical trials and regulatory approvals for current and future product candidates[187] - The company has significant contractual obligations totaling $66.4 million, with $7.99 million due within one year and $14.8 million due in the next one to three years[196] - The company experienced a $120.5 million decrease in net operating assets and liabilities during the nine months ended September 30, 2025, primarily due to a decrease in deferred revenue from the termination of a collaboration agreement[190] Economic Factors - Inflation has not had a material effect on the company's financial statements, although it has increased costs related to labor and laboratory consumables[208] - Future disruptions in financial institutions could adversely affect the company's ability to access cash and cash equivalents[207] - The company is classified as an "emerging growth company" under the JOBS Act, allowing it to take advantage of reduced reporting requirements[198]

Core Insights - Century Therapeutics is advancing its iPSC-derived cell therapies targeting autoimmune diseases and cancer, with a focus on Type 1 diabetes (T1D) and B-cell-mediated diseases [2][5][6] Business Update - The company announced its lead iPSC-derived beta islet program for T1D, with plans to initiate IND-enabling studies by the end of 2025 and submit an IND as early as 2026 [2][5][6] - CNTY-308 is progressing through IND-enabling studies, aiming for clinical study initiation in 2026 [5][6] - CNTY-101 is continuing in a Phase 1/2 investigator-sponsored trial, with initial clinical data expected in December 2025 [6] Financial Results - As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $132.7 million, down from $220.1 million at the end of 2024, with an estimated cash runway into Q4 2027 [6][10] - R&D expenses for Q3 2025 were $22.5 million, a decrease from $27.2 million in Q3 2024, primarily due to reduced personnel and manufacturing costs [6][10] - G&A expenses were $6.8 million for Q3 2025, down from $8.4 million in Q3 2024, attributed to a gain on lease modification [10] - The net loss for Q3 2025 was $34.4 million, compared to a net loss of $31.2 million for the same period in 2024 [10][13]

Core Insights - Century Therapeutics has announced its first program for Type 1 diabetes (T1D), CNTY-813, utilizing iPSC-derived beta islets engineered with Allo-Evasion™ 5.0 technology to achieve durable glycemic control without systemic immunosuppression [1][2][5] Company Overview - Century Therapeutics is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies aimed at addressing autoimmune diseases and cancer [7] - The company leverages its proprietary Allo-Evasion™ technology to create off-the-shelf cell therapies that enhance patient access and offer advantages over existing treatments [7] Product Development - The CNTY-813 program aims to provide a scalable, immune-evasive beta islet therapy that could significantly improve the treatment landscape for T1D, which affects approximately 9 million people globally, including 2 million in the U.S. [4][5] - Century has generated compelling preclinical data demonstrating rapid and sustained normalization of glucose levels in diabetic mouse models, along with significant glucose-stimulated insulin secretion and engineered resistance to immune rejection [2][6] - The company plans to initiate IND-enabling studies by the end of 2025 and aims to submit an IND application to the FDA as early as 2026 [3][5] Market Opportunity - The current treatment for T1D imposes a significant financial burden on the healthcare system, with annual insulin costs in the U.S. estimated between $6 billion and $8 billion [4] - An off-the-shelf, immune-evasive beta islet therapy could provide a paradigm shift in T1D management, addressing the challenges of unpredictable glucose swings and the need for lifelong insulin [2][4]

Century Therapeutics Conference Call Summary Company Overview - **Company Name**: Century Therapeutics (Ticker: IPSC) - **Industry**: Biotechnology, specifically focused on induced pluripotent stem cells (iPSCs) and cell therapies Key Points and Arguments Clinical Programs - **CNTY-101**: An NK cell-based therapy with a CD19 CAR, currently in clinical trials in the U.S. and EU, targeting autoimmune diseases [3][20] - **CNTY-308**: A preclinical program targeting B-cell-mediated diseases, expected to enter clinical trials mid-next year [4] - **Non-Immune Cell Program**: A highly anticipated program that is not disclosed for competitive reasons but is believed to have significant potential [4] Scientific Advancements - **Cell Foundry**: Century's capability to produce adult functional cells from iPSCs, including CD4 and CD8 T cells, which are crucial for treating B-cell malignancies and autoimmune diseases [5][6] - **Alloevasion Technology**: Century is a leader in immune evasion strategies, with advancements from alloevasion 1.0 to 5.0, allowing for better protection of allogeneic cells from the patient's immune system [6][7][9] Pipeline and Efficacy - **Efficacy of T Cells**: The company claims that their iPSC-derived T cells can perform comparably to autologous T cells, with the ability to engage targets and proliferate effectively [15][16] - **Long-term Durability**: The combination of CD4 and CD8 T cells enhances long-term durability and effectiveness in tumor control [17][18] Clinical Trials and Results - **Calypso Trial**: A company-sponsored trial for CNTY-101, allowing for re-dosing without lymphodepletion, showing promise in autoimmune diseases [20][21] - **B Cell Malignancy Trial**: Previous trials demonstrated deep and sustained B cell depletion, indicating the potential for effective treatment in autoimmune diseases [23][24] Financial and Operational Updates - **Cash Runway**: The company has extended its cash runway through 2027, allowing for continued development and data collection from ongoing trials [7] - **Restructuring**: A recent restructuring has focused the company on key assets and streamlined operations [7] Additional Important Information - **Cost-Effectiveness**: The company aims to produce therapies at costs comparable to antibody treatments, which could enhance accessibility [22] - **Safety Profile**: NK cell therapies are noted for their favorable safety profile compared to T cell therapies, which can have severe side effects [22] - **Future Directions**: The company is exploring the possibility of reducing or eliminating lymphodepletion in trial designs, which could further enhance treatment options [28][29] This summary encapsulates the key insights from the conference call, highlighting Century Therapeutics' innovative approaches in the biotechnology sector, particularly in cell therapy and immune evasion strategies.

Core Insights - Century Therapeutics, Inc. is focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies targeting autoimmune diseases and cancer [1][3] - Chad Cowan, Ph.D., the Chief Scientific Officer, will present at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025 [1] - The company utilizes its proprietary Allo-Evasion™ technology to enhance immune evasion in its therapies, aiming to improve patient access and treatment outcomes [3] Company Overview - Century Therapeutics is a clinical-stage biotechnology firm listed on NASDAQ under the ticker IPSC [3] - The company is advancing a pipeline of iPSC-derived cell therapies, which are designed to address significant medical needs in autoimmune diseases and cancer [3] - The therapies are produced from the company's iPSC cell foundry, indicating a focus on innovative and scalable treatment solutions [3] Presentation Details - The presentation by Chad Cowan will take place at 12:20 p.m. ET in New York, NY [1] - A live webcast of the presentation will be accessible on the company's Investors page, with an archived replay available for at least 30 days [2]